Alexandra N Bogomazova
Overview
Explore the profile of Alexandra N Bogomazova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shnaider P, Malyants I, Ivanova O, Gordeeva V, Svirina E, Zakharzhevskaya N, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769003
High-grade serous ovarian carcinoma (HGSOC) remains the most common and deadly form of ovarian cancer. However, available cell lines usually fail to appropriately represent its complex molecular and histological features....
2.
Goliusova D, Sharikova M, Lavrenteva K, Lebedeva O, Muranova L, Gusev N, et al.
Biochemistry (Mosc)
. 2024 Oct;
89(9):1546-1557.
PMID: 39418514
Filamin C (FLNC) is a member of a high-molecular weight protein family, which bind actin filaments in the cytoskeleton of various cells. In human genome FLNC is encoded by the...
3.
Kudriavskii V, Goncharov A, Eremeev A, Ruchko E, Veselovsky V, Klimina K, et al.
Biochemistry (Mosc)
. 2024 Sep;
89(8):1474-1489.
PMID: 39245456
Expansion of CAG repeats in certain genes is a known cause of several neurodegenerative diseases, but exact mechanism behind this is not yet fully understood. It is believed that the...
4.
Shender V, Anufrieva K, Shnaider P, Arapidi G, Pavlyukov M, Ivanova O, et al.
Nat Commun
. 2024 Jul;
15(1):6450.
PMID: 39085258
No abstract available.
5.
Shender V, Anufrieva K, Shnaider P, Arapidi G, Pavlyukov M, Ivanova O, et al.
Nat Commun
. 2024 Jun;
15(1):5237.
PMID: 38898005
Ovarian cancer often develops resistance to conventional therapies, hampering their effectiveness. Here, using ex vivo paired ovarian cancer ascites obtained before and after chemotherapy and in vitro therapy-induced secretomes, we...
6.
Bogomiakova M, Bogomazova A, Lagarkova M
Biochemistry (Mosc)
. 2024 Jun;
89(5):799-816.
PMID: 38880643
Induced pluripotent stem cells (iPSCs), capable of differentiating into any cell type, are a promising tool for solving the problem of donor organ shortage. In addition, reprogramming technology makes it...
7.
Benedetti M, DAndrea T, Colantoni A, Silachev D, de Turris V, Boussadia Z, et al.
Heliyon
. 2024 Mar;
10(5):e26656.
PMID: 38434323
Pathogenic variants in the gene, encoding the alpha subunit of an inhibitory heterotrimeric guanine nucleotide-binding protein (Go) highly expressed in the mammalian brain, have been linked to encephalopathy characterized by...
8.
Oshkolova A, Grekhnev D, Kruchinina A, Belikova L, Volovikov E, Lebedeva O, et al.
Biochimie
. 2024 Jan;
222:63-71.
PMID: 38163516
Disease models based on induced pluripotent stem cells (iPSCs) are in high demand because of their physiological adequacy and well-reproducibility of the pathological phenotype. Nowadays, the most common approach to...
9.
Lebedeva O, Sharova E, Grekhnev D, Skorodumova L, Kopylova I, Vassina E, et al.
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108456
About 15% of patients with parkinsonism have a hereditary form of Parkinson's disease (PD). Studies on the early stages of PD pathogenesis are challenging due to the lack of relevant...
10.
Bogomiakova M, Sekretova E, Anufrieva K, Khabarova P, Kazakova A, Bobrovsky P, et al.
Stem Cell Res Ther
. 2023 Apr;
14(1):77.
PMID: 37038186
Background: Dozens of transplants generated from pluripotent stem cells are currently in clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible due to their main advantage of immunotolerance....